Behavioral Neuroscience, Attention, Executive functions, Psychopharmacology, Cognitive Aging, Alzheimer’s disease, Schizophrenia, Addiction
Dr. Parikh received his doctoral degree in Life Sciences/Pharmacology from Punjabi University in 1999. After serving as a Research Scientist in the Drug Discovery Group at Sun Pharmaceutical Industries Ltd. for two years, he joined the Medical College of Georgia as a postdoctoral fellow to obtain training in Neurochemistry and Neuropsychopharmacology. He integrated perspectives of systems and behavioral/cognitive neuroscience into his research by acquiring further postdoctoral training in Psychobiology and Neuroscience from the Ohio State University and the University of Michigan. Prior to joining Temple as Assistant Professor (tenure-track) in 2009, he held the position of Assistant Research Scientist in the Department of Psychology (Biopsychology Program) at the University of Michigan.
Dr. Parikh’s primary research focuses on the neurochemistry of cognition with special emphasis on attention and executive functions. He is interested in understanding how neurochemical signaling systems, specifically the neurotransmitters and trophic factors, process information in discrete brain circuits to support vigilance, attentional switching, working memory, flexible decision-making and cognitive control of behavior. Additionally, he studies cognitive aging and mechanisms regulating the cognitive reserve capacity. As cognitive impairments represent an important attribute of major neuropsychiatric disorders and age-related neurodegenerative disorders such as schizophrenia, drug addiction and Alzheimer’s disease, Dr. Parikh’s research has major implications for understanding the neurochemical basis of attentional and executive deficits associated with these pathologies. The long term goal of his research is to identify potential biomarkers to develop psychotherapeu tic approaches for the treatment of brain disorders with dysfunctional cognitive abilities. Dr. Parikh utilizes an integrative multidisciplinary approach to understand brain-behavioral relationships in both normal and pathological conditions. Some of the techniques routinely used in his lab are in vivo extracellular electrochemical recordings to monitor real time changes in synaptic transmission, operant paradigms to assess cognitive functions in rodents, and genetic and biochemical approaches including the use of transgenic mice and vector-based RNAi methods, immunohistochemistry, cell imaging, western blotting and PCR. Dr. Parikh’s research is published in many high impact neuroscience journals and is funded by the National Institute of Health, Brain and Behavior Research Foundation and the American Federation for Aging Research.
1) Parikh V, Naughton SX, Shi X, Kelley LK, Yegla B, Tallarida CS, Rawls SM, Unterwald EM. Cocaine-induced neuroadaptations in the dorsal striatum: glutamate dynamics and behavioral sensitization. Neurochemistry International 2014; (in press).
2) Yegla B, Parikh V. Effects of sustained proNGF blockade on attentional capacities in aged rats with compromised cholinergic system. Neuroscience 2014; 261:118-132.
3) D’Amore DE, Tracy BA, Parikh V. Exogenous BDNF facilitates strategy shifting by modulating glutamate dynamics in the dorsal striatum. Neuropharmacology 2013; 75:312-323.
4) Ortega LA, Tracy BA, Gould TJ, Parikh V. Effect of chronic low- and high-dose nicotine on cognitive flexibility in C57BL/6J mice. Behavioral Brain Research 2013; 238: 134-145.
5) Parikh V, St. Peters M, Blakely RD, Sarter M. The presynaptic choline transporter imposes limits on sustained cortical acetylcholine release and attention. The Journal of Neuroscience 2013; 33:2326-2337.
6) Parikh V, Howe WM, Welchko R, Naughton SX, Han D, D’Amore DE, Turner DL, Sarter M. Diminished trkA receptor signaling reveals cholinergic-attentional vulnerability of aging. European Journal of Neuroscience 2013; 37:278-293.
7) Parikh V, Sarter M. Regulation and functions of forebrain cholinergic systems: new insights based on rapid detection of choline spikes using enzyme-based biosensors. In: Microelectrode Biosensors (Dale N, Marinesco S, eds), 2013,
Neuromethods: Springer Protocols Vol 80, PP 257-273, Humana Press Inc., New York.
8) Parikh V, Ji J, Decker MW, Sarter M. Prefrontal β2 subunit-containing and α7 nAChRs differentially control glutamatergic and cholinergic signaling. The Journal of Neuroscience 2010; 30:3518-3530.
9) Parikh V, Sarter M. Cognitive decline in laboratory animals: models, measures, and validity. In: Encyclopedia of Behavioral Neuroscience (Koob G, Thompson RF, LeMoal M, eds), 2010, Vol 1, pp 294-301, Amsterdam, Netherlands: Elsevier.
10) Parikh V, Sarter M. Cholinergic mediation of attention: the contribution of phasic versus tonic components of prefrontal cholinergic activity. Annals of the New York Academia of Sciences 2008; 1129: 225-235.
11) Parikh V, Kozak R, Martinez V, Sarter M. Prefrontal acetylcholine release controls cue detection on multiple time scales. Neuron 2007; 56: 141-54.
12) Sarter M, Parikh V. Choline transporters, cholinergic transmission and cognition. Nature Reviews Neuroscience 2005; 6:48-56.
13) Parikh V, Terry AV, Khan MM, Mahadik SP. Modulation of nerve growth factor and choline acetyltransferase expression in rat hippocampus after chronic exposure with haloperidol, risperidone and olanzapine. Psychopharmacology 2004; 172:365-
14) Parikh V, Evans DR, Khan MM, Mahadik SP. Nerve growth factor levels in never-medicated first-episode psychotic patients and medicated chronic schizophrenic patients. Schizophrenia Research 2003; 60:117-123.
Cellular and Molecular Neuroscience
Techniques in Neuroscience
Writing-intensive Capstone in Neuroscience
Neurobiology of Executive Function and Dysfunction